A number of other brokerages also recently weighed in on XLRN. Credit Suisse Group increased their price target on Acceleron Pharma from $99.00 to $123.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Piper Sandler reiterated a “buy” rating and set a $135.00 price target on shares of Acceleron Pharma in a report on Monday, April 6th. Citigroup increased their price target on Acceleron Pharma from $136.00 to $137.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. SVB Leerink increased their price objective on shares of Acceleron Pharma from $104.00 to $127.00 in a research report on Tuesday, May 12th. Finally, Goldman Sachs Group cut shares of Acceleron Pharma from a “neutral” rating to a “sell” rating and set a $73.00 price objective on the stock. in a research report on Monday, April 6th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have issued a buy rating to the company. Acceleron Pharma has an average rating of “Buy” and a consensus price target of $111.92.
NASDAQ XLRN opened at $104.80 on Wednesday. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.04. The stock has a fifty day simple moving average of $98.22 and a 200 day simple moving average of $81.09. Acceleron Pharma has a twelve month low of $37.60 and a twelve month high of $110.49. The company has a market capitalization of $5.46 billion, a price-to-earnings ratio of -40.46 and a beta of 0.77.
In related news, SVP Adam M. Veness sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $85.58, for a total value of $513,480.00. Following the transaction, the senior vice president now owns 27,161 shares of the company’s stock, valued at approximately $2,324,438.38. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Kevin F. Mclaughlin sold 36,774 shares of the firm’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $85.51, for a total transaction of $3,144,544.74. Following the completion of the transaction, the chief financial officer now directly owns 15,216 shares in the company, valued at approximately $1,301,120.16. The disclosure for this sale can be found here. 2.50% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the business. FDx Advisors Inc. purchased a new stake in Acceleron Pharma in the 1st quarter valued at about $34,000. Chevy Chase Trust Holdings Inc. purchased a new stake in Acceleron Pharma in the 4th quarter valued at about $36,000. Ladenburg Thalmann Financial Services Inc. increased its stake in Acceleron Pharma by 33.9% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,063 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 269 shares during the last quarter. Advisor Group Holdings Inc. purchased a new stake in Acceleron Pharma in the 1st quarter valued at about $60,000. Finally, Tower Research Capital LLC TRC increased its stake in Acceleron Pharma by 554.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 1,048 shares during the last quarter. Hedge funds and other institutional investors own 88.46% of the company’s stock.
Acceleron Pharma Company Profile
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.